[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588403":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":17,"studyPopulation":17,"armGroups":26,"interventions":39,"overallOfficials":17,"centralContacts":45,"locations":51,"responsibleParty":69,"collaborators":74,"id":113,"slug":17,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":114,"sex":120,"minAge":17,"maxAge":17,"enrollmentInfo":121,"targetDuration":17,"studyType":124,"phases":125,"briefSummary":127,"conditions":128,"keywords":17,"overallStatus":54,"whyStopped":17,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},{"fullName":5,"class":6},"Norwegian Department of Health and Social Affairs","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":17},[9,13],{"measure":10,"description":11,"timeFrame":12},"Rate of severe adverse events, re-admissions and deaths within 30 days","co-primary short-term endpoint is the composite rate of rate of severe adverse events, re-admissions and deaths within 30 days following assigned treatment","30 days",{"measure":14,"description":15,"timeFrame":16},"Rate of cancer recurrence or CRC death after three years","primary long-term endpoint of CRC death or cancer recurrence or sign of lymph nodes or distant metastases after three years","3 years",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":24},"SINGLE",[25],"OUTCOMES_ASSESSOR",[27,33],{"label":28,"type":29,"description":30,"interventionNames":31},"eFTR","EXPERIMENTAL","endoscopic full thickness resection",[32],"Procedure: eFTR",{"label":34,"type":35,"description":36,"interventionNames":37},"Surgery","ACTIVE_COMPARATOR","standard-of-care surgery",[38],"Procedure: Surgery",[40,43],{"type":41,"name":28,"description":30,"armGroupLabels":42,"otherNames":17},"PROCEDURE",[28],{"type":41,"name":34,"description":36,"armGroupLabels":44,"otherNames":17},[34],[46],{"name":47,"role":48,"phone":49,"phoneExt":17,"email":50},"MICHAEL BRETTHAUER, MD PhD","CONTACT","+4790132480","michael.bretthauer@medisin.uio.no",[52],{"facility":53,"status":54,"city":55,"state":17,"zip":17,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Medical University of Gdańsk","RECRUITING","Gdansk","Poland","PL",{"type":59,"coordinates":60},"Point",[61,62],18.64912,54.35227,{"lat":62,"lon":61},[65],{"name":66,"role":48,"phone":67,"phoneExt":17,"email":68},"Piotr Spychalski, MD PhD","90132480","piotr.spychalski@gmail.com",{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":73,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Michael Bretthauer","Professor","Oslo University Hospital",[75,78,80,82,85,87,89,91,93,95,97,99,101,103,105,107,109,111],{"name":76,"class":77},"Medical University of Gdansk","OTHER",{"name":79,"class":77},"Vestre Viken Hospital Trust",{"name":81,"class":77},"Universitätsklinikum Hamburg-Eppendorf",{"name":83,"class":84},"Institute of Oncology in Warsaw","UNKNOWN",{"name":86,"class":77},"Karolinska Institutet",{"name":88,"class":77},"University Hospital, Limoges",{"name":90,"class":77},"University Hospital, Akershus",{"name":92,"class":77},"University of Roma La Sapienza",{"name":94,"class":77},"Hospital Clinic of Barcelona",{"name":96,"class":84},"Leuven University Medical Center",{"name":98,"class":77},"University Hospital, Ghent",{"name":100,"class":6},"Sorlandet Hospital HF",{"name":102,"class":84},"Northern Norway Regional Health Trust",{"name":104,"class":6},"Helse Stavanger HF",{"name":106,"class":77},"Haukeland University Hospital",{"name":108,"class":77},"St. Olavs Hospital",{"name":110,"class":77},"University of Oslo",{"name":112,"class":84},"Frontier Science Foundation","100588403",false,"NCT06940947","Endoscopic Therapy Or Surgery for Early Colon Cancer","Endoscopic THerapy Or Surgery for Early Colon Cancer (ETHOS)","ETHOS","Inclusion Criteria:\n\n* Newly diagnosed biopsy-confirmed colon cancer (adenocarcinoma) with macroscopic suspicion of submucosal invasion considered removable by EFTR as deemed by the local multidisciplinary team (MDT) at the participating center\n* Size ≤20 mm in diameter as deemed by the colonoscopist\n* No presence of histopathological high-risk features in biopsy (high grade tumor growth, budding grade 2 or 3, or lymphovascular invasion)\n* Patient eligible for surgical removal as deemed by the local MDT at the participating center\n* Endoscopic images or video of the tumor\n* No sign of disease beyond T2N0M0 on pre-treatment imaging, biopsy sampling, and radiographic and clinical evaluation\n* No contraindication for any of the two treatment arms\n* Written informed consent\n* No prior or synchronous CRC\n* No other malignancy which is not cured\n* No more than 10 adenomas or serrated polyps\n* No genetic cancer syndrome (adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome)\n* No inflammatory bowel disease","ALL",{"count":122,"type":123},434,"ESTIMATED","INTERVENTIONAL",[126],"PHASE3","The trial is a randomized head-to-head comparison of the benefits, harms and burdens of endoscopic full-thickness resection (eFTR), a novel, minimally invasive endoscopic treatment modality, for early colon cancer as compared to standard-of-care surgery.",[129],"Colon Cancer","2025-11-17",{"date":132,"type":133},"2025-11-20","ACTUAL",{"date":135,"type":133},"2025-08-25",{"date":137,"type":123},"2033-09-01",{"name":5,"class":6},1]